This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub
Menü
Schließen
AboutRecommendationsDosing and AdministrationEfficacy and SafetyEfficacy ProfileSafety ProfileSupport and ResourcesEventsMaterialsVideos

ABRYSVO is also indicated for active immunisation of individuals 60 years of age and above for prevention of lower respiratory tract disease caused by RSV.1 Click here for more information. 

EVERY BREATH MATTERS.Don’t let RSV take her baby’s breath away.

ABRYSVO is the FIRST and ONLY* maternal vaccine to help protect infants against lower respiratory tract disease (LRTD) caused by
respiratory syncytial virus (RSV),from first breath.1-2

ABRYSVO is now funded on the NIP for pregnant women2 view schedule

ABRYSVO is recommended year-round for active immunisation of pregnant women between 28–36 weeks gestation, to help protect infants against severe RSV disease from birth through to 6 months of age.2

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

 Recommendations Loading Dosing and Administration Loading Reconstitution LoadingRSV is a major cause of LRTD in infants and young children5
Paediatric hospitalisations with RSV as a principal diagnosisLRTD due to RSV is a leading cause of hospitalisation in infants, with most hospitalisations in Australia occurring in infants aged under 6 months.5
  • Infants are more than 12x as likely to be admitted to hospital with RSV as children aged 1–4 years.5
  • RSV is responsible for 8x as many hospitalisations as influenza in children <5 years.6
  • In Indigenous children <6 months old, the rate of hospitalisation due to RSV is almost double that of non-Indigenous children.5
Up to 80% of infants and children hospitalised with RSV are otherwise healthy,
with no underlying health issues.7 

ABRYSVO is one of the 3 vaccines routinely recommended in pregnancy8 

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

‡ 81.8% vaccine efficacy against severe medically attended lower respiratory tract disease caused by RSV in infants from birth through 90 days of age (99.5% CI: 40.6%, 96.3%). Vaccine efficacy at 120 days (73.9 [97.58% CI 45.6, 88.8]), 150 days (70.9 [97.58% CI 44.5, 85.9]) and 180 days (69.4 [97.58% CI 44.3, 84.1]). Vaccine efficacy results met the statistical criterion for success of a CI lower bound >20% for reducing severe medically-attended LRTD due to RSV.1
ABRYSVO can be given at the same time, or separately to dTpa, influenza and COVID-19.2 Learn more about vaccination in pregnancyLoading

Pregnant woman receives ABRYSVO between 28 and 36 weeks of pregnancy.1

Infant is born with maternal antibodies, which help protect against LRTD caused by RSV from birth through 6 months.2

Pregnant woman’s immune system produces antibodies, which are passed through the placenta to the foetus.1

Infant is born with maternal antibodies, which help protect against LRTD caused by RSV from birth through 6 months.9

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is now funded on the NIP for pregnant women3 and is one of 3 vaccines routinely recommended in pregnancy4. 

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

 Learn more Loading Abrysvo®

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 Zur Produktseite Maternal Loading Zur Produktseite Ältere Erwachsene Loading Fachinformation Loading
LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus.
*As of February 2025References:ABRYSVO Approved Product Information.Respiratory syncytial virus (RSV), Australian Immunisation Handbook. Accessed January 2025. Avaliable at Respiratory syncytial virus (RSV) | The Australian Immunisation HandbookGreen LJ, et al. Obstet Gynecol. 2020;135(3):653–664.4.Data on fileSaravanos GL, et al. Med J Aust. 2019;210(10):447–453.Nazareno AL, et al. Influenza Other Respir Viruses. 2022;16:1082–1090Time to Act: Protecting our children from RSV. Evoheatth(2023).Vaccination for women who are planning pregnancy, pregnant or breastfeeding | The Australian Immunisation Handbook. Available at https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-women-who-are-planning-pregnancy-pregnant-or-breastfeedingKampmann B, et al. N Engl J Med. 2023;388(16):1451–1464.

Before prescribing, please review Product Information available here.

▼This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems 

PBS Information: ABRYSVO is listed on the NIP for pregnant women (28–36 weeks gestation) only and is not listed on the PBS.

PP-A1G-AUS-0272. 02/25.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0551 12/23.
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​